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Abstract 
Objective 
The incidence and outcome of first episode Substance Induced Psychotic Disorder 
(SIPD) is unclear. The study aimed to compare the 1-year outcomes of those given a 
SIPD diagnosis by clinicians compared to other psychosis diagnoses in a first episode 
cohort.  
Method 
Data was from a large (n=1027) cohort of First Episode Psychosis (FEP) patients 
admitted to early intervention services in the UK (National EDEN). Diagnosis, 
including that of SIPD, was made by treating psychiatrists at baseline using ICD10 
criteria. Details on symptoms, functioning, quality of life, relapse and recovery was 
available at baseline and 12 months.  
Results 
There were 67 cases of SIPD (6.5% of the cohort). At baseline SIPD patients were no 
different to other psychoses on symptoms, functioning and quality of life. At 12 
months there was no difference in SIPD and other psychoses on functioning, quality 
of life or relapse and recovery rates. Levels of psychotic and general symptomatology 
were similar but depressive symptoms were higher in the SIPD group.  
Conclusions 
FEP patients with a diagnosis of SIPD do not appear to have better outcomes that 
those with other primary psychotic diagnoses. The higher levels of depressive 
symptoms may be a specific marker in these patients.  
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Significant outcomes 
 There were no differences in baseline symptoms and functioning levels 
between those with a clinician diagnosis of substance induced psychotic 
disorder (SIPD) and other psychosis diagnoses in a large first episode 
psychosis cohort. 
 At 12 months follow-up there were higher levels of depressive symptoms in 
those with SIPD compared to those with other psychosis diagnoses.  
 There were no differences in other outcomes between the SIPD and other 
psychosis groups at 12 month follow-up including other symptomatic or 
functional outcomes, rates of relapse and recovery. 
Limitations 
 The diagnosis of SIPD was made by clinicians using ICD 10 criteria and not 
using a specific validated diagnostic tool. The diagnosis was only possible if 
patients disclosed their substance use. 
 The numbers of individuals with SIPD was relatively low reducing the ability 
to identify small differences in outcome. 
 Treatment offered to the two diagnostic groups over the 12 month period were 
not fully characterized. 
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Introduction 
Since the early 1990’s the Early Intervention in Psychosis (EIP) movement has led to 
services reconfiguration in the UK and worldwide with specialist Early Intervention 
(EI) teams developed which aim to treat emerging psychotic disorder and improve 
functional outcomes (1). The early intervention paradigm has assumed a symptom 
“threshold” (in terms of frequency and intensity) approach for what constitutes 
psychosis (2) that encompasses a range of disorders, from schizophrenia spectrum 
disorders, mood disorders with psychosis, and substance induced psychotic disorder 
(SIPD). However, there is debate on whether the treatment of persistent psychotic 
symptoms assumed to be in the context of other primary disorders should be the remit 
of EI teams (3). 
 
One particular area of debate is whether SIPD should be treated in the same manner 
as other psychoses within these services, or even referred to these services in the first 
place (3). This is predicated on the widespread assumption that outcomes for SIPD 
are different to other psychotic disorders. The current International Classification of 
Diseases ICD10 (4) defines SIPD as “a cluster of psychotic phenomena that occur 
during or following psychoactive substance use but that are not explained on the basis 
of acute intoxication alone and do not form part of a withdrawal state” although the 
category of residual and late-onset psychotic disorder would also be considered here, 
though often presenting at a later age (ICD 10). The prevalence of SIPD has been 
estimated to be 1.9/100,000 person years, which is around 5% of all case of psychosis 
(5). However, as lifetime prevalence of substance use in first episode patients is high, 
as is the levels of substance use at presentation to services (6), diagnostic difficulties 
are common. Studies have reported the diagnosis of SIPD is relatively unstable and 
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there is a considerable “progression” to more schizophreniform diagnoses (7-9). A 
follow-up sample with a primary psychotic disorder plus substance use and those with 
SIPD revealed that they also receive different treatment approaches such as 
differential prescribing of antipsychotic medication (10). Other studies have reported 
that SIPD patients are less likely to be hospitalized, less likely to be started on 
antipsychotics and referred to psychiatry that those with primary psychotic disorder 
(11). Clinically, this is usually justified on the basis of an assumption that SIPD has a 
good short-term prognosis, will be short lived and self-limiting with ultimate 
resolution being provided by abstinence from the substance. Good quality evidence 
for these widespread clinical assumptions is however lacking (12) and the current 
evidence is conflicting with some studies suggesting there is a good outcome (10) and 
other reporting high rates of psychotic relapse in SIPD (8).  
 
Given these findings of diagnostic instability and uncertain outcomes there is a lack of 
clarity on the most suitable care pathway that should be instituted for these patients 
presenting with a first episode psychosis (FEP). In a critical review of SIPD, the 
authors identified only 18 articles specifically focusing on delineating the clinical 
characteristics or outcomes and only 1 that reported 1 year follow up data (12). There 
have been no studies to our knowledge that have investigated both symptomatic and 
functional outcomes in incident cases of SIPD compared to other diagnostic groups. 
This information would have considerable implications for treatment and follow-up of 
these patients. For example, should the outcomes be substantially better, there may be 
an argument for shorter or less intensive treatment pathways. 
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Aims of the study 
The study aimed to investigate the 12-month outcome of first episode psychosis 
patients in a large UK FEP cohort who were diagnosed with a SIPD compared to 
other psychotic disorders. There were two hypotheses: 1) functional outcomes in 
SIPD would be similar to other psychotic disorders 2) symptomatic outcomes would 
be better in the SIPD group than for other psychotic disorders and they would 
experience fewer relapses. 
 
Methods and materials 
Sample 
The data was taken from the national EDEN database (13) of 1027 FEP cases 
admitted to EI services between August 2005 to April 2009 from five geographical 
sites across England: Birmingham, Cornwall, Cambridge, Norwich and Lancashire 
(13). National EDEN was a study of outcomes in UK Early Intervention Services. The 
UK Department of Health guidance for inclusion into these services is broad and 
requires only that patients are ‘aged between 14 and 35 with a first presentation of 
psychotic symptoms’ (14). Data was recorded throughout the treatment with the 
service up to 12 months. For further details of the sample see Birchwood et al (13). 
The treatment pathway in EI services is determined by the UK National Institute for 
Health and Care Excellent guideline for Schizophrenia and Psychosis (15) and the 
national IRIS Early Psychosis guidelines (16). The standard length of treatment for 
any patient accepted into an EI service in the UK is 3 years. Team structure for EI 
teams in the UK has previously been recommended by the Department of Health (14).  
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Ethical approval for the study was given by Suffolk Local Research Ethics 
Committee, UK. 
 
Diagnostic groups 
Research assistants recorded ICD 10 diagnoses made by the treating consultant at 
entry to the service from the clinical files.  The OPerational CRITeria (OPCRIT) 
diagnostic system was also used in the cohort but OPCRIT does not give a diagnosis 
of SIPD as one of the outputs (17). There was a number of diagnoses made including 
substance induced psychosis, schizophrenia, schizoaffective disorder, bipolar 
disorder, delusional disorder and unspecified psychosis. Unspecified psychosis was 
the largest diagnostic group, likely due to these clinical diagnoses being made at first 
contact with services when duration of symptoms may be less clear, symptoms fluid 
and a generic diagnosis of “first episode psychosis” (or unspecified psychosis) 
common practice in UK early psychosis services. Those with a diagnosis of SIPD 
were compared to the overall group of other psychosis diagnoses. 
 
Outcome measures  
A number of symptom and functional outcomes were available at 12-month follow-up 
as well as at baseline in the cohort.  
i) Symptoms 
The following symptom scales were available at baseline and 12 months: Positive and 
Negative Syndrome Scale (PANSS), yielding total, general, negative and positive 
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symptoms scores (18)); The Young Mania Rating scale (YMRS) (19); The Calgary 
Depression Scale (20); The Global Assessment of Functioning (GAF) scale (21) 
(symptoms indicated by GAF total, GAF symptoms). 
ii) Functioning and quality of life measures 
The following functioning and quality of life measures were used that were collected 
at baseline and 12 months: The Global Assessment of Functioning (GAF) scale (21) 
(functioning indicated by GAF total, GAF disability); EuroQual 5 Dimensions 
Questionnaire (EQ-5D) (22) (using the overall score and the health thermometer 
score); Time use survey (23). 
iii) Relapse and recovery 
Using standard international definitions of relapse and recovery from the Bebbington 
et al method (24). This was summated at 12 months to give rates for both of these 
outcomes at this time point. 
 
Analyses 
The baseline characteristics of those with a diagnosis of SIPD with the group with 
other psychosis diagnoses were compared statistically using analysis of variance and 
chi-squared tests. A regression model was used to investigate outcome by diagnostic 
group, with the individual outcome of interest at 12 months as the independent 
variable and diagnostic group as the dependent variable. Covariates in an adjusted 
model included age, gender, ethnicity, Duration of Untreated Psychosis (DUP) and 
baseline outcome scores. Analyses were performed using SPSS version 22.  
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Results 
Of the 1027 cases in the National EDEN database, there were 954 (92.9%) individuals 
with a recorded clinician diagnosis at baseline (entry to the service). Of these 954 
individuals, 685 (66.7%) had a diagnosis of unspecified psychosis, 136 (13.2%) 
schizophrenia, 50 (4.9%) bipolar disorder, 16 (1.6%) schizoaffective disorder and 67 
(6.5%) SIPD. The patients used a multitude of substances and the rate of previous 
illicit substance use was high in the total sample (65.2%). However, when 
investigating the primary substance used in both the SIPD and other psychosis groups 
this was predominantly cannabis (93.7% in the other psychosis group and 93.8% in 
the SIPD group). The SIPD group were far more likely to use more than one 
substance, for example the percentage of the SIPD group reporting use of a second 
substance was 75.6% compared to 37.8% in the other psychoses group. However, it 
was not specified which, if any of the substances used, was implicated as the primary 
cause of the SIPD.  
 
Baseline characteristics of the sample 
The baseline characteristics of the sample are presented in Table 1. There were no 
significant differences in demographic characteristics between SIPD and the other 
psychoses group (see Table 1). There were there also no significant differences 
between the two diagnostic groups at baseline on symptoms, functioning and quality 
of life (see Table 2) with the only (expected) difference being the lifetime use of 
substances. 
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Insert Table 1 around here 
   Insert Table 2 around here 
 
Differences at 12 months outcome 
At 12 months post diagnosis there were few differences between the SIPD group and 
the other psychosis group. Scores on functioning, quality of life and rates of relapse 
and recovery were not different between the two groups. This was the case for both 
the unadjusted analyses and the analysis adjusted for age, gender, ethnicity, DUP and 
baseline score. The only significant difference on symptoms was that the SIPD group 
scored higher on the Calgary Depression Scale (both unadjusted and adjusted for age, 
gender, ethnicity, DUP and baseline Calgary score) (see Table 3). Rates of substance 
use in the 3 months prior to follow-up were still significantly higher in the SIPD 
group than the other psychosis group 55.1% in the SIPD group and 25.2% in the other 
psychosis group, p<0.001). 
 
   Insert Table 3 around here 
 
Discussion 
Summary of results 
In this study the outcome of the clinician diagnosis of SIPD compared to other 
psychotic diagnoses was compared using data from a large FEP cohort. The study 
found that functional outcomes for individuals with SIPD were not different to those 
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with other primary psychotic disorders. This supported the first hypothesis which was 
functional outcomes in SIPD would be similar to other psychotic disorders. The 
functional and quality of life outcomes were improved for all disorders but remain 
relatively low for SIPD despite 12 months of treatment in an EI service. However, 
contrary to the second hypothesis, levels of relapse and recovery were similar in the 
SIPD and other psychosis group. The only difference on symptomatic outcome was 
that the SIPD group had higher levels of depression at 12 months.  
 
Comparison to other research 
There have been few other research studies comparing the outcome of first episode 
SIPD to other psychotic disorders. In a critical review of SIPD, the authors identified 
only 18 articles specifically focusing on delineating the clinical characteristics or 
outcomes and only 1 that reported 1 year follow up data (12). A report from the US 
highlighted differences between SIPD and those with primary psychosis and 
concurrent substance use at baseline (25). In terms of symptoms they reported that the 
SIPD group had more visual hallucinations but that the primary psychosis group had 
higher scores in the PANNS negative, positive and general scales as well as lower 
insight scores. Remission rates were also higher in the SIPD group (26). This was not 
the case in this cohort. There are some differences in the samples, which might 
explain these differences. Although the above sample was first episode sample, 
patients were recruited from emergency departments in the US whereas our sample 
was from all patients accepted into UK EI services, which is the modal pathway for 
first episode treatment in the UK. It may also be that the treatments provided to these 
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Others have suggested that there may be distinct psychopathological differences 
between SIPD and primary psychosis, including levels of affective symptoms (27) 
and this might help to distinguish the diagnosis of SIPD from primary psychotic 
disorders with substance use. Related to this is the suggestion of high rates of 
progression to an affective disorder in this group as well as a psychotic disorder (28). 
The current study also found that affective symptoms, especially depressive 
symptoms at follow-up, were different in the two groups. At present we are unsure if 
this reflects different treatment pathways, worse adherence to treatment in this group, 
the consequences of continued significant substance use, or an affective marker in 
these patients, but this would warrant further study. Others have found different 
factors that are able to predict the diagnosis of SIPD versus a primary psychotic 
disorder including family history of psychosis, trauma history and current cannabis 
dependence (29) and distinct differences in symptom profile at baseline (30). There 
may also be some differences due to the type of substance inducing the psychotic 
disorder (31). There is also work investigating whether there are neurobiological 
differences to distinguish these two diagnostic groups (32). We found no differences 
other than prior history of substance use to distinguish these groups at baseline in our 
cohort. 
 
Strengths and limitations 
The numbers in the overall National EDEN database are large and it represents the 
largest cohort of FEP patients receiving treatment available currently. However, the 
numbers of individuals with SIPD are still relatively low (n=67). Given the relatively 
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small numbers in the SIPD group estimation was conducted with relatively low 
precision, especially with regard to the difference in symptomatic outcome and 
relapse. However, there were multiple symptom measures available, the confidence 
intervals for most of the symptom measures in the SIPD group were relatively narrow 
and the finding of increased levels of depression in the SIPD was supported by extant 
literature. There were some missing data on both symptoms and functioning for both 
groups but this was relatively modest. Hence a missing data analysis was not 
performed. The diagnosis of SIPD was made by the consultant psychiatrist in the EI 
service using ICD 10 criteria and recorded by the researcher but the diagnosis was not 
made using a structured interview such as the SCAN (33). Therefore, our results 
essentially reflect the outcome of what psychiatrists believe represents a diagnosis of 
SIPD at entry to an EI service. Whilst this might indicate a reduced reliability of 
diagnosis in research terms, our findings on the other hand do strongly represent 
routine clinical practice and have considerable face validity and clinical relevance. 
OPCRIT (15) diagnoses were available for this cohort, but OPCRIT does not give a 
diagnosis of SIPD as an output. The diagnosis of SIPD has been shown to have 
reasonable validity, although with some caveats (12), and does encompass psychosis 
induced by a variety of psychoactive substances, with some possible differences in 
presentation between these (34). The rate of SIPD diagnosis in the cohort as a whole 
(6.5%) is similar to the published incidence rates for all psychotic disorders versus 
SIPD’s (5). However, further research is needed in first episode psychosis samples 
using validated and reliable diagnostic tools to substantiate these findings. In this 
sample we do have a high number of non-specific diagnoses (unspecified psychosis) 
made by clinicians likely due to the widespread practice of giving a non specific 
psychosis diagnosis on entry to EI services but some clinicians have made the 
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decision on the diagnosis of SIPD early in the course. We are not clear whether this 
reflects a degree of certainty from the clinician or a tendency to attribute an 
aetiological (and possibly less stigmatizing) cause for the presentation. We were 
unable to compare the specific treatments that the diagnostic groups received. The 
treatment offered by EI services in the UK is a broadly consistent 3-year program, 
following NICE guidance (15), although specifically tailored by the individual patient 
formulation and to some extent the diagnosis. Lastly, we are aware that we have 
investigated the relatively short-term outcome of these patients and there is a need to 
consider the long-term outcome further. 
 
 
Clinical implications 
The results have implications for both those who refer to EI services such as 
emergency departments, acute services and other community psychiatric teams and 
for the treatment of patients with SIPD within these services. EI services have debated 
whether SIPD should be treated within their teams and at times these patients 
anecdotally have not been referred to EI services (3). The results from this study 
would suggest that outcomes of patients given this diagnosis by psychiatrists are not 
significantly more favourable, in fact they possibly have poorer affective outcomes. In 
this respect, they are in need of a service based on both symptomatic and functional 
outcomes. As such this may argue for a more assertive treatment approach for this 
group and challenge clinical strategy based on the view that long-term follow-up is 
not required. The incidence of SIPD reported in a recent meta-analysis is 1.9/100,000 
person years is not insignificant (5). The literature on the rates of development 
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schizophreniform disorder in those with an initial diagnosis of SIPD would suggest 
that EI services are best placed to provide this service, especially if the teams have 
specific training in treatment of dual diagnosis. Having said this, the predictors of 
poor outcome in SIPD are relatively understudied and knowledge of these predictors 
would help to “stream” treatment approaches within services. Our work suggests that 
psychosis linked to substance misuse has poor outcomes, whether the substance 
misuse is a seen as ‘comorbidity’, or a risk factor, or deemed to have triggered the 
psychosis. The treatment of depressive symptoms needs further emphasis, especially 
as we know that substance use is a risk factor for suicide in FEP patients (35). 
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Table 1: Baseline demographics and substance use of the sample by diagnostic group 
 Other 
Psychoses* 
 
Substance 
Induced 
Psychotic 
Disorder * 
Total* P value 
Age at onset (N=929) 21.3 (5.0) 20.7 (4.4) 21.3 (5.0) 0.354 
Gender (N= 954), male (%) 608 (68.5%) 50 (75.8%) 658 (69.0%) 0.135 
DUP (N=940), Mean (SD)  328.3 (670.5) 154.7 (243.5) 316.1 (651.2) 0.037 
Educational level/Qualifications 
(N=939) 
None 
Basic (GCSE/NVQ ½) 
Advanced (A level/BTEC/NVQ3) 
Degree/HND/NVQ 4+ 
Special needs educational 
qualifications 
 
 
 
212 (24.3%) 
339 (38.8%) 
230 (26.3%) 
88 (10.1%) 
5 (0.6%) 
 
 
18 (27.3%) 
30 (45.5%) 
15 (22.7%) 
3 (4.5%) 
0 (0%) 
 
 
 
230 (24.5%) 
368 (39.2%) 
245 (26.1%) 
91 (9.7%) 
5 (0.5%) 
 
 
0.511 
Ethnicity (N=954) 
Asian 
Black 
Caucasian 
Mixed 
Other 
 
128 (14.4%) 
58 (6.5%) 
660 (74.3%) 
35 (3.9%) 
7 (0.8%) 
 
11 (16.4%) 
1 (1.5%) 
51 (76.1%) 
4 (6.0%) 
0 (0%) 
 
139 (14.6%) 
59 (6.2%) 
710 (74.4%) 
39 (4.1%) 
7 (0.7%) 
 
0.416 
Living circumstances (N=951) 
Alone 
With parents/guardians 
With partner 
Other 
 
118 (13.3%) 
554 (62.6%) 
94 (10.6%) 
119 (13.4%) 
 
3 (4.5%) 
47 (70.1%) 
6 (9.0%) 
11 (16.4%) 
 
121 (12.7%) 
601 (63.2%) 
100 (10.5%) 
129 (13.6%) 
 
0.194 
Occupational circumstances 
(N=949) 
Working (paid) 
Working (voluntary) 
Unemployed 
Homemaker 
Student 
Other 
 
 
161 (18.2%) 
9 (1.0%) 
511 (57.8%) 
20 (2.3%) 
172 (19.5%) 
11 (1.2%) 
 
 
11 (16.7%) 
0 (0.0%) 
43 (65.2%) 
2 (3.0%) 
10 (15.2%) 
0 (0.0%) 
 
 
172 (18.1%) 
9 (0.9%) 
553 (58.3%) 
22 (2.3%) 
182 (19.2%) 
11 (1.2%) 
 
 
0.745 
* N for SIPD = 67, for other psychosis = 887 and total = 954, number vary slightly by individual variable 
Footnote: DUP=Duration of Untreated Psychosis; GCSE= General Certificate of Secondary Education; 
NVQ=National Vocational Qualification; BTEC= Business and Technology Educational Council; HND=Higher 
National Diploma 
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Table 2: Baseline symptoms and functioning scores by diagnostic group 
  
Other Psychoses* Substance Induced 
Psychotic disorder* 
Total* P 
value 
GAF total  N  
Mean score (SD) 
837 
50.1 (17.1) 
60 
52.9 (16.7) 
897 
50.3 (17.0) 
0.188 
GAF symptoms  N  
Mean score (SD) 
827 
51.1 (16.6) 
61 
52.5 (17.3) 
888 
51.2 (16.6) 
0.488 
GAF disability  N  
Mean score (SD) 
825 
52.9 (15.2) 
61 
53.7 (15.6) 
886 
52.9 (15.2) 
0.577 
Calgary 
Depression Scale 
N  
Mean score (SD) 
832 
6.5 (5.4) 
58 
5.6 (4.7) 
890 
6.4 (5.4) 
0.250 
YMRS  N  
Mean score (SD) 
832 
6.0 (7.3) 
56 
6.5(7.5) 
888 
6.1(7.3) 
0.658 
Insight scale  N  
Mean score (SD) 
616 
7.75 (3.0) 
51 
7.90 (3.0) 
667 
7.76 (3.0) 
0.731 
Lifetime 
substance use  
Yes  
No 
557(64.6%) 
305 (35.4%) 
66 (98.5%) 
1 (0.3%) 
622 (67.0%) 
306 (33.0%) 
 
<0.001 
PANSS positive  N  
Mean score (SD) 
827 
15.4(6.0) 
61 
15.6 (6.7) 
888 
15.4 (6.1) 
0.843 
PANSS negative  N  
Mean score (SD) 
806 
15.0 (6.4) 
60 
14.2 (7.8) 
866 
14.9 (6.5) 
0.349 
PANSS general  N  
Mean score (SD) 
817 
33.2 (10.0) 
58 
31.5 (9.5) 
875 
33.1 (10.0) 
0.258 
PANSS total  N  
Mean score (SD) 
798 
63.3 (18.7) 
58 
61.7  (17.5) 
856 
63.2 (18.8) 
0.527 
EQ-5D health 
thermometer 
N  
Mean score (SD) 
723 
60.6 (21.9) 
53 
62.4 (21.9) 
776 
60.7 (21.9) 
0.555 
EQ – 5D total 
score  
N  
Mean score (SD) 
768 
6.9 (1.7) 
59 
6.9 (1.6) 
827 
6.9 (1.7) 
0.937 
 
*overall N for SIPD = 67, for other psychosis = 887 and total = 954, number vary slightly by individual 
symptom outcome 
Footnote: GAF= Global Assessment of Functioning scale; YMRS= Young Mania Rating Scale; 
PANSS= Positive and Negative Syndrome Scale; EQ= EuroQol 
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Table 3: 12 month symptom and functional outcome for SIPD and others psychosis 
unadjusted and adjusted for age/gender/ethnicity/DUP and baseline score 
 
 
Unadjusted  Adjusted* 
  
Other 
Psychosis 
Substance 
induced 
psychotic 
disorder 
P 
value 
 Other 
psychosis  
Substance  
induced 
psychotic 
disorder 
P 
value 
GAF total N 
Mean score 
95% CI 
723           
62.6           
(61.3-64.0) 
53             
65.3         
(60.3-70.3) 
0.307 N 
Mean score 
95% CI 
696          62.4     
(61.1-63.7) 
52              
63.8        
(59.0-68.6) 
0.595 
GAF disability N 
Mean score 
95% CI 
715           
62.9        
(61.7-64.2) 
51             
64.2        
(59.5-69.0) 
0.602 N 
Mean score 
95% CI 
688            
62.6        
(61.3-63.8) 
50              
63.1        
(58.6-67.6) 
0.821 
GAF symptoms N 
Mean score 
95% CI 
715            
63.8         
(62.6-65.0) 
51             
67.3         
(62.8-71.9) 
0.139 N 
Mean score 
95% CI 
688           
63.6        
(62.4-64.9) 
50              
66.6        
(62.1-71.1) 
0.212 
PANSS total  N 
Mean score 
95% CI 
671           
49.2         
(48.0-50.4) 
48                
48.8        
(44.4-53.1) 
0.838 N 
Mean score 
95% CI 
591           
49.1        
(47.9-50.3) 
45              
48.9         
(44.5-53.2) 
0.922 
PANSS positive N 
Mean score 
95% CI 
680              
11.3         
(10.9-11.6) 
48              
11.2          
(9.9-12.5) 
0.947 N 
Mean score 
95% CI 
615            
11.3         
(11.0-11.6) 
45              
11.0          
(9.8-12.3) 
0.685 
PANSS negative N 
Mean score 
95% CI 
674             
12.1        
(11.7-12.5) 
48             
11.9         
(10.3-13.4) 
0.803 N 
Mean score 
95% CI 
599            
12.1         
(11.6-12.5) 
45              
12.2        
(10.7-13.7) 
0.832 
PANSS general N 
Mean score 
95% CI 
676                
26.0         
(25.4-26.6) 
48                
25.7         
(23.4-28.0) 
0.794 N 
Mean score 
95% CI 
608           
25.9         
(25.2-26.5) 
45              
25.7         
(23.4-28.0) 
0.887 
Calgary Depression 
Scale 
N 
Mean score 
95% CI 
688             
3.5                 
(3.2-3.8) 
46               
5.0            
(3.8-6.2) 
0.032 N 
Mean score 
95% CI 
628                
3.6                
(3.2-3.9) 
42                
5.2              
(3.9-6.4) 
0.015 
YMRS N 
Mean score 
95% CI 
696              
3.2              
(2.8-3.6) 
47               
3.4             
(1.9-4.8) 
0.824 N 
Mean score 
95% CI 
636               
3.2               
(2.8-3.6) 
43                
3.5                
(2.0-5.0) 
0.743 
EQ 5D total N 
Mean score 
95% CI 
640              
6.2            
(6.1-6.3) 
44               
6.3              
(5.9-6.7) 
0.666 N 
Mean score 
95% CI 
613                     
6.3            
(6.1-6.4) 
43                  
6.2            
(5.8-6.7) 
0.886 
EQ 5D health 
thermometer 
N 
Mean score 
95% CI 
608              
66.7        
(65.0-68.4) 
37               
66.2        
(59.5-73.0) 
0.895 N 
Mean score 
95% CI 
582              
67.2          
(65.5-68.9) 
39              
66.7        
(60.2-73.2) 
0.890 
Relapse (%)              
None 
Type 2 exacerbation 
Type 1 true 
 
 
561 (63.2%) 
125 (14.1%) 
73     (8.2%) 
 
35    (53.0%) 
11    (16.7%) 
9      (13.6%) 
 
 
0.309 
    
 
0.247 
Recovery (%)      
None                                
Partial  
Full 
 
 
91    (10.2%) 
262 (29.5%) 
506 (57.0%) 
 
7      (10.6%) 
20    (30.3%) 
37    (56.1%) 
 
0.998 
    
0.364 
* adjusted analysis with age, gender, ethnicity, DUP (Duration of Untreated Psychosis) and baseline scores as 
covariates, apart from the analyses for relapse and recovery when baseline scores were not a covariate 
Footnote: GAF= Global Assessment of Functioning scale; YMRS= Young Mania Rating Scale; PANSS= Positive 
and Negative Syndrome Scale; EQ= EuroQol 
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